前列地尔治疗支气管哮喘的效果

Effect of Alprostadil in the treatment of bronchial asthma

目的探讨前列地尔治疗支气管哮喘的临床效果。方法选取2016年7月~2017年12月我院收治的78例支气管哮喘患者作为研究对象,按照治疗方法的不同分为常规组和研究组,每组各39例。常规组给予抗感染、止咳化痰对症治疗,研究组在常规组的常规治疗方案基础上给予前列地尔治疗。比较两组患者的肺功能及血清白细胞介素-4(IL-4)、白细胞介素-12(IL-12)和干扰素-γ(IFN-γ)水平。结果研究组的治疗总有效率为97.44%,明显高于常规组的84.62%,差异有统计学意义(P<0.05)。研究组治疗后的肺功能指标(FEV1、FVC、FEV1%)和血清IL-12、IFN-γ水平均明显高于常规组,差异有统计学意义(P<0.05)。研究组治疗后的血清IL-4水平明显低于常规组,差异有统计学意义(P<0.05)。结论前列地尔治疗支气管哮喘患者能够有效改善肺功能,抑制炎症因子,疗效显著,值得临床推广应用。

Objective To explore the clinical effect of Alprostadil in the treatment of bronchial asthma. Methods From July 2016 to December 2017, a total of 78 cases of bronchial asthma in our hospital were selected and divided into the routine group and the research group according to different treatment methods, 39 cases in each group. The routine group was given anti-infection, cough relieving and expectorant symptomatic treatment, while the study group was given Alprostadil based on the conventional treatment regimen of the routine group. The lung function and serum levels of IL-4, IL-12 and IFN-γ were compared between the two groups. Results The total effective rate of the study group was97.44%, which was significantly higher than 84.62% of the routine group, with significant difference（P〈0.05）. After treatment, the indexes of lung function（FEV1, FVC, FEV1%） and the level of serum IL-12, IFN-γ in the study group were significantly higher than those in the routine group（P〈0.05）, and the level of serum IL-4 in the study group was significantly lower than that of the routine group, with significant difference（P〈0.05）. Conclusion Alprostadil in the treatment of bronchial asthma can effectively improve lung function, inhibit inflammatory factors, and has obvious clinical curative effect. It is worthy of clinical promotion and application.